The Schwab U.S. Dividend Equity ETF (SCHD) is recommended as a core holding for long-term investors seeking diversified dividend income. With a 3% dividend yield (three times higher than S&P 500 ETFs), low 0.06% expense ratio, and exposure to stable sectors like healthcare and consumer staples, SCHD offers attractive passive income potential. The ETF has delivered 29% total returns year-to-date and is particularly suitable for tax-advantaged accounts like Roth IRAs.

Abbott Laboratories, a Dividend King with 54 consecutive years of dividend increases, is positioned as a defensive investment for potential market downturns. The company reported strong Q2 results with 13% sales growth and raised its full-year EPS guidance. With a 46% payout ratio and growth catalysts from medical devices and its $21 billion Exact Sciences acquisition in cancer diagnostics, Abbott offers both income stability and growth potential.

Novocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.

The Schwab U.S. Dividend Equity ETF (SCHD) has delivered a 57% total return over three years and is recommended as a strong buy for income-focused investors seeking stability and diversification. While the fund offers solid dividend growth (7.53% annually) and exposure to mature, profitable companies, its limited tech exposure (8.2%) means it will miss out on AI-driven gains that boosted the Nasdaq-100 by 92%. The outlook remains positive for the next five years if the U.S. economy continues growing, though trade policy uncertainty and rising bond yields present near-term risks.

Schwab U.S. Dividend Equity ETF (SCHD) offers nearly double the dividend yield of Vanguard Dividend Appreciation ETF (VIG) at 3% versus 1.5%, with a value-focused portfolio in healthcare and consumer defensives. VIG emphasizes technology stocks and requires 10-year dividend growth streaks. SCHD showed stronger one-year returns (29.5% vs 17.1%) and lower volatility, making it the analyst's preferred choice for income investors seeking higher yields.

The global Baby Food and Infant Formula Market was valued at USD 40.37 billion in 2025 and is projected to reach USD 74.30 billion by 2035, growing at a CAGR of 6.29%. Growth is driven by urbanization, increasing parental health consciousness, demand for organic/premium products, and e-commerce expansion. However, recent product recalls by major manufacturers highlight safety concerns in the industry.

The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.

The Invesco Pharmaceuticals ETF (PJP) is a passively managed fund tracking the Dynamic Pharmaceutical Intellidex Index with $541.13 million in assets. It offers broad exposure to U.S. pharmaceutical companies with a 0.57% expense ratio and 0.82% dividend yield. The ETF has gained 24.96% year-to-date and 41.74% over the past year but carries higher risk with a beta of 0.45 and 16.02% standard deviation. It holds 32 stocks with top positions in Abbott Laboratories, Amgen, and Abbvie, and carries a Zacks ETF Rank of 3 (Hold).

As concerns grow about a potential AI market slowdown due to inflation, rate hikes, and geopolitical tensions, investors should consider diversifying into dividend-focused ETFs like SCHD. The Schwab U.S. Dividend Equity ETF offers exposure to 100 stable, dividend-paying stocks across multiple sectors, providing a defensive hedge against AI stock volatility while delivering steady income and historical returns of 243% over the past decade.

A Motley Fool contributor recommends the Schwab U.S. Dividend Equity ETF (SCHD) as a single buy-and-hold dividend investment. The ETF tracks 100 U.S. stocks with consistent dividend histories and strong fundamentals, features an ultra-low 0.06% expense ratio, and holds well-known companies like Home Depot, Merck, and Procter & Gamble with evenly weighted top holdings to diffuse risk.

The iShares U.S. Medical Devices ETF (IHI) is reviewed as a passively managed fund offering diversified exposure to the healthcare medical devices sector. With $3.44 billion in assets and a 0.37% expense ratio, IHI tracks the Dow Jones U.S. Select Medical Equipment Index. The fund has declined 12.46% year-to-date and carries a Zacks ETF Rank of 3 (Hold), making it a reasonable but not exceptional choice for sector exposure.

The National Advertising Division ruled on a challenge by Abbott Laboratories against Kendamil infant formula. While NAD supported claims about whole milk ingredients, it recommended Kendamil discontinue or modify claims regarding nutritional superiority over competitors, breast milk comparisons, HMO immune health benefits, and brand heritage dating to 1962. Kendamil stated it will comply with NAD's recommendations.